Brexpiprazole

證據等級: L5

預測適應症: 10 個

Brexpiprazole: From Major Depressive Disorder to Dysthymic Disorder

One-Sentence Summary

Brexpiprazole (Rexulti) is a serotonin-dopamine activity modulator (SDAM) with FDA approval for schizophrenia and as an adjunctive treatment for major depressive disorder (MDD); it is not currently registered on the Australian Register of Therapeutic Goods (ARTG). The TxGNN model predicts it may be effective for Dysthymic Disorder (now classified as Persistent Depressive Disorder under DSM-5), supported by a plausible mechanistic rationale given its overlapping pathophysiology with MDD. However, there are currently no registered clinical trials and no directly supporting publications for this specific indication, placing the evidence at L4 — a hypothesis that requires dedicated clinical investigation before further steps can be taken.

Quick Overview

Item	Content
Original Indication	Schizophrenia (monotherapy); Major Depressive Disorder (adjunctive) — FDA-approved; not TGA-registered in Australia
Predicted New Indication	Dysthymic Disorder
TxGNN Prediction Score	98.53%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) — the second D2 partial agonist to reach the market after aripiprazole. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A and adrenergic α1B receptors. Compared to aripiprazole, brexpiprazole has lower intrinsic D2 activity and substantially higher potency at 5-HT1A and α1B sites. This receptor profile is directly relevant to mood regulation, motivational drive, and anhedonia — all core features of depressive illness. Multiple Phase 3 RCTs support its efficacy as an adjunct to antidepressants in patients with MDD and inadequate response, and the drug has received FDA approval for both schizophrenia and adjunctive MDD treatment.

Dysthymic disorder — formally designated Persistent Depressive Disorder (PDD) in DSM-5 — shares significant pathophysiological overlap with MDD, including sustained dysregulation of dopaminergic and serotonergic circuits in the prefrontal cortex, hippocampus, and limbic system. Brexpiprazole’s D2 partial agonism is thought to modulate mesolimbic dopaminergic output (relevant to chronic anhedonia), while 5-HT1A partial agonism may restore prefrontal cortical serotonin function — both mechanisms directly applicable to the persistent low mood, fatigue, and anhedonia characteristic of dysthymia. The TxGNN model’s high prediction score (98.53%) is therefore biologically coherent.

That said, meaningful caveats apply. The degree and pattern of dopamine/serotonin dysregulation in chronic, low-grade depression is thought to differ from that in acute MDD episodes. All existing Phase 3 RCT populations for brexpiprazole were recruited under DSM-IV/5 MDD criteria — not dysthymia or PDD — and the response to augmentation strategies in chronic low-grade depression may differ substantially. No dedicated studies in dysthymic disorder currently exist. This remains a well-motivated but clinically untested hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered for Brexpiprazole in dysthymic disorder.

Literature Evidence

Currently no related literature directly addressing Brexpiprazole in dysthymic disorder.

Note for clinicians: Substantial indirect evidence for brexpiprazole in the broader depressive spectrum (MDD and treatment-resistant depression) is available in the related indications within this evidence pack. Highlights include a Phase 3 RCT by Thase et al. (2015, J Clin Psychiatry; PMID 26301701), a dose-effect meta-analysis by Furukawa et al. (2022, Psychiatry Clin Neurosci; PMID 35716011), and a systematic review/NMA by Guo et al. (2024, Psychiatry Res; PMID 38924903). These are captured under the “Neurotic Depression” (Rank 5) and “Melancholia” (Rank 6) indications in the full evidence pack, both of which carry L3 evidence.

Safety Considerations

Brexpiprazole is not registered on the ARTG; no TGA-approved Australian Product Information (PI) exists. Please refer to the US FDA prescribing information (Rexulti® — Otsuka America Pharmaceutical / Lundbeck) for the full safety profile.

From internationally available data, the following class-level and drug-specific considerations are relevant:

Antipsychotic class effects: Metabolic syndrome risk (weight gain, dyslipidaemia, hyperglycaemia), extrapyramidal symptoms, tardive dyskinesia risk (lower than first-generation antipsychotics but non-negligible with long-term use), QTc prolongation, orthostatic hypotension (α1B antagonism).
Brexpiprazole-specific: Akathisia (lower frequency than aripiprazole), somnolence, weight gain (moderate), and visual disturbances including blurred vision — the latter warrants particular caution if use in ophthalmologically relevant indications is ever considered.
Special populations: The FDA added a boxed warning for increased mortality risk in elderly patients with dementia-related psychosis (class warning for all atypical antipsychotics). Brexpiprazole has also received FDA approval for agitation in Alzheimer’s disease (2023), which may be relevant to future expanded indication discussions.

Conclusion and Next Steps

Decision: Hold

Rationale: There is currently no direct clinical evidence — neither registered clinical trials nor specific publications — supporting brexpiprazole for dysthymic disorder. While the SDAM mechanism provides a biologically coherent rationale grounded in shared pathophysiology with MDD, mechanistic plausibility alone is insufficient to support clinical use. Furthermore, brexpiprazole is not registered in Australia; any use would require navigation of TGA access pathways prior to any clinical application.

To proceed, the following is needed:

Dedicated clinical trial data for brexpiprazole in dysthymic disorder / Persistent Depressive Disorder (PDD); consider a Phase 2 proof-of-concept design using augmentation in antidepressant-refractory PDD patients
Systematic review to determine whether any existing MDD Phase 3 trial subpopulations overlap meaningfully with PDD/dysthymic criteria (e.g., chronic course subgroup analyses)
TGA registration pathway assessment — options include Special Access Scheme (SAS) Category B for individual patient access, Authorised Prescriber designation, or full ARTG registration via the TGA’s comparable overseas regulator (COR) pathway recognising FDA approval
Full Australian-compliant Product Information (PI) and Risk Management Plan for any regulatory submission
Assessment of PBS listing feasibility and pharmacoeconomic modelling for the Australian context

⚠️ Disclaimer: This report is intended for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All content should be interpreted in the context of applicable TGA regulations and individual clinical judgement.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.